PAK2驱动的细胞骨-内基因组动力学控制巨细胞过和SIRPA参与
Julie Drieu La Rochelle1, Joseph P Cassidy2, Jonathan Chernoff3
1Conway Institute, School of Medicine, University College Dublin, Dublin 4, Ireland.
概括
抑制氨酸/氨酸激酶PAK2可增强巨细胞吞和SIRPA封存,为癌症提供一种新的免疫疗法策略. 这种方法通过改变巨细胞的功能来促进癌细胞的杀死.
科学领域:
- 免疫学 免疫学 免疫学
- 细胞生物学 细胞生物学
- 生物化学 生化学
背景情况:
- 巨细胞表现出细胞骨的可塑性,这对组织稳态和免疫反应至关重要.
- 瘤微环境对巨细胞进行重新编程,从而产生多样化,往往免疫抑制的表型.
- 调节巨细胞骨动力学在癌症免疫治疗中提供了治疗潜力.
研究的目的:
- 研究氨酸/氨酸激酶PAK2在调节巨细胞功能中的作用.
- 为了确定是否准PAK2可以重编程巨细胞以增强癌细胞杀死.
- 探索PAK2抑制对免疫反应和组织完整性的体内影响.
主要方法:
- 基因操纵以消除巨细胞中的PAK2活性.
- 评估巨细胞膜动态和细胞容量.
- 分析内体受体贩运,包括SIRPA回收利用.
- 在体内研究检查PAK1/PAK2在炎症和恶性瘤模型中的合作.
主要成果:
- 取消PAK2活动诱导了显著的膜扩张和放大了各种目标的吞.
- 发现PAK2对于协调内分体受体贩运,特别是SIRPA细胞表面循环,至关重要.
- 在体内,PAK1和PAK2协作限制氧化应激并保持肠道屏障的完整性.
- 在低度炎症背景下,PAK2抑制促进了巨细胞驱动的血液恶性瘤.
结论:
- 准PAK2改变了巨细胞的特性,增强了它们的细胞和杀癌潜力.
- PAK2抑制提供了一个有前途的免疫疗法策略,通过利用过和SIRPA封存.
- 了解PAK2的作用对于开发利用巨效应因子功能的新癌症治疗方法至关重要.
相关概念视频
Phosphoinositides and PIPs
10.0K
Phosphoinositides are a group of phospholipids containing a glycerol backbone with two fatty acid chains and a phosphate attached to a myoinositol sugar ring. The inositol head group extends into the cytoplasm, where it is modified by adding phosphate groups to form phosphatidylinositol phosphates or PIPs.
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
10.0K
PI3K/mTOR/AKT Signaling Pathway
5.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
5.3K
Cancer Cell Migration through Invadopodia
3.2K
Invadosome is a broad category of cell surface structures with proteolytic activity that degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
3.2K
Mechanism of Filopodia Formation
3.0K
Filopodia are thin, actin-rich cellular protrusions that play an important role in many fundamental cellular functions. They vary in their occurrence, length, and positioning in different cell types, suggesting their diverse roles.
Their main function is to guide migrating cells during normal tissue morphogenesis or cancer metastasis by recognizing and making initial contacts with the extracellular matrix. However, they can also act as stationary cell anchors or help to establish communication...
Their main function is to guide migrating cells during normal tissue morphogenesis or cancer metastasis by recognizing and making initial contacts with the extracellular matrix. However, they can also act as stationary cell anchors or help to establish communication...
3.0K
Phagocytosis of Apoptotic Cells
4.9K
Cells undergoing apoptosis form apoptotic bodies that must be removed immediately to prevent inflammation, autoimmune diseases, and necrosis. Phagocytosis is carried out by professional phagocytes such as macrophages or immature dendritic cells. Non-professional phagocytes such as epithelial cells and fibroblasts also take part in this process; however, they are not as effective as professional phagocytes.
Normal cells contain receptors that prevent them from being recognized...
Normal cells contain receptors that prevent them from being recognized...
4.9K
The JAK-STAT Signaling Pathway
11.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
11.9K


